Global In-Situ Hybridization Market By Technology(Fluorescent In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH)) By Probe Type( DNA, RNA) By Application(Cancer, Developmental Biology, Cytogenetics, Infectious Diseases, Other Applications) End-User(By Research & Diagnostic Laboratories, CROs, Academic Institutes, Other End-Users) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2033
- Published date: Dec 2023
- Report ID: 35658
- Number of Pages: 285
The Global In situ Hybridization Market size is expected to be worth around USD 2.8 Billion by 2033 from USD 1.5 Billion in 2023, growing at a CAGR of 6.8% during the forecast period from 2024 to 2033.
In-situ hybridization is a laboratory technique employed by researchers to pinpoint specific DNA/RNA sequences within chromosomes. Molecular hybridization utilizes DNA’s ability to reform or renature under favorable conditions; during this technique a labeled DNA or RNA sequence acts as a probe to identify, locate or quantify naturally occurring sequences in biological samples; the nucleic acid probe must first be synthesized, labeled, purified, then annealed with its target; this technique also plays an integral part in genetic research as well as explorations into gene-based medicine, especially personalized medical.
In-situ hybridization can be divided into two general categories depending on the probes used; FISH uses fluorescence probes while CISH relies on chromogenic probes. FISH allows multiple targets to be seen at once in one sample and is often employed for gene detection and mutation analysis; CISH provides tissue morphological information through genetic profiling, making it especially helpful in molecular pathology diagnostics.
*Actual Numbers Might Vary In The Final Report
- Market Size & Growth: In situ Hybridization Market size is expected to be worth around USD 2.8 Billion by 2032 from USD 1.5 Billion in 2023, growing at a CAGR of 6.8%
- Technology analysis: Based on technology, conquered the Fluorescent In Situ Hybridization (FISH) held the major revenue share at 58% in 2023.
- Probe Type analysis: The in-Situ hybridization market was dominated by DNA probes, accounting for 56% revenue share in 2023.
- Application analysis: In-Situ hybridization is a market that dominates the cancer segment. It accounted for the largest revenue share at 41.2% in 2023.
- End-Use analysis: Research & Diagnostic Laboratories dominated the In-Situ hybridization market and held the largest revenue share at 50% in 2023.
- Regional Analysis: North America dominated In-Situ Hybridization in 2023, accounting for 46.6% revenue share and holding USD 0.6 Billion revenue.
The FISH segment, based on technology, conquered the Fluorescent In Situ Hybridization (FISH) held the major revenue share at 58% in 2023. This is due to the broad range of applications like diagnosing congenital conditions such as Down’s Syndrome and Edward’s Syndrome. FISH technology is being used more frequently due to the rising numbers of these diseases and their analysis. It is expected that this will accelerate the growth of the segment.
CISH has also seen a substantial share of in-situ hybridization, as it is an affordable, reliable, and practical alternative to FISH. CISH technology is able to detect HER-2/neu copies using conventional peroxidase reactions. CISH technology will be accepted more widely for HPV genotyping on cervical smears. The market is expected to grow further over the forecast period. The segment growth is driven by technological advancements in ISH.
Researchers published their study, which showed that the chromogen-based RNA-In-Situ hybridization approach is a reliable method to detect drug-gable substances in psoriasis and atopic dermatitis. Technological advancements increase the reach of in-situ hybridization and stimulate segment growth.
Probe Type analysis
The in-Situ hybridization market was dominated by DNA probes, accounting for 56% revenue share in 2023. The RNA probe had a faster growth rate than the DNA probe segment, thanks to the advancement of nucleic acids-based diagnostic assays, tools, and methods for analyzing DNA and RNA molecules. An RNA probe is used for hybridization to detect the presence or absence of complementary nucleic acid sequences.
RNA probes are becoming increasingly popular as a tool for hybridization. They can be used to detect the presence of complementary nucleic acid sequences by hybridization and can be replaced with DNA probes in almost any application. It is possible to explain the high CAGR of 2024-2033 because RNA has a single-stranded signal that is more reliable than DNA probes. The ISH market will grow if there is more development in probe-based technology.
In-Situ hybridization is a market that dominates the cancer segment. It accounted for the largest revenue share at 41.2% in 2023. It is expected that the growth will be driven by the rising incidence of cancer cases. According to the American Cancer Society, approximately 1.9 Million new cases of cancer will be reported in the U.S. by 2021.
Due to an increase in cancer cases, In-Situ hybridization techniques are becoming more important for efficient and rapid diagnosis. Cancers can be caused by unhealthy lifestyles, aging populations, environmental factors, and health conditions. Numerous organizations support research into cancer treatment and encourage further development. In 2020-21, the American Institute for Cancer Research provided approximately USD 110 million in funding for cancer research through its grant program.
Research & Diagnostic Laboratories dominated the In-Situ hybridization market and held the largest revenue share at 50% in 2023. There are three major end users in the market: hospitals and diagnostic laboratories, and academic and research institutes. The current pandemic could be a key driver for laboratories, as the ability to understand the pathogen and offer competitive advantages to them can help to lead the industry.
Although the absolute value is lower than other segments, the Contract Research Organizations market is growing at an even faster rate. Many organizations outsource clinical trials and research to research laboratories. Factors like a specialized workforce can reduce costs for companies. Companies may also be motivated by improving efficiency to outsource their research.
*Actual Numbers Might Vary In The Final Report
Kеу Маrkеt Ѕеgmеnt
- Fluorescent In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
- Developmental Biology
- Infectious Diseases
- Other Applications
- Research & Diagnostic Laboratories
- Academic Institutes
- Other End-Users
*Actual Numbers Might Vary In The Final Report
Precision Medicine Adoption
One key driver in the in situ hybridization market is an increasing emphasis on precision medicine. As healthcare trends move toward personalized treatment approaches, in situ hybridization techniques play a vital role in identifying specific DNA/RNA sequences associated with individual patients – creating targeted therapies and thus driving demand for these technologies.
Expanding Applications in Cancer Research
In situ hybridization’s increasing applications in cancer research contribute significantly to its market expansion. This technique enables researchers to analyze genetic abnormalities at the cellular level, helping in the identification of cancer markers, understanding tumor heterogeneity and making treatment decisions more effectively. With cancer becoming more prevalent worldwide, demand for advanced in situ hybridization technologies increases significantly.
Integrating Automation and Digitalization
Notable trends in the in situ hybridization market include automation and digitalization. Advancements in technology have allowed for the creation of automated in situ hybridization platforms that maximize efficiency, reduce turnaround times, and improve accuracy; digitalization enables easier analysis, storage, sharing and research workflow efficiencies thereby streamlining research workflows.
Multiplex In Situ Hybridization Techniques
Multiplex in situ hybridization techniques have rapidly become the next hot trend among researchers, who now seek methods that enable simultaneous visualization of multiple target DNA/RNA sequences within one sample. Multiplexing enhances genetic analysis’s comprehensiveness by providing more data about complex cellular processes and interactions within cells.
Complexity and Expertise Requirements
One key impediment to in situ hybridization market growth is its complexity and the expertise needed for accurate interpretation. Conducting in situ hybridization assays requires high levels of technical skill and knowledge that makes performing them inaccessible to researchers without prior training; this poses a barrier for widespread adoption, impeding market expansion.
Advanced techniques tend to be costly
Cost-intensive nature of advanced in situ hybridization techniques acts as a deterrent. Implementation of cutting-edge technologies, like fluorescence in situ hybridization (FISH), may involve significant upfront costs for laboratories; budget constraints could prevent the adoption of advanced techniques within resource-constrained settings.
Diagnostics and Pathology Services Experience Growing Demand
One opportunity in the in situ hybridization market lies in its increasing usage for diagnostic applications, particularly pathology. More and more clinics use in situ hybridization for genetic abnormality detection as well as infectious agent detection; pathology applications of in situ hybridization offer significant growth avenues as part of routine diagnostic procedures.
Novel Probes and Assay Kits
Innovative probe designs and assay kits present market players with an opportunity. By continually innovating probe designs and assay kits, innovation increases specificity, sensitivity and ease-of-use when used for in situ hybridization techniques. Manufacturers focusing on creating user-friendly, cost-effective and customizable solutions may take advantage of an increasing demand for such tools.
North America dominated In-Situ Hybridization in 2023, accounting for 46.6% revenue share and holding USD 0.6 Billion revenue. This region has seen significant growth due to the presence of many market players and the incentivized research projects of the regional government. Other factors that contributed to the dominance in the region are high healthcare expenditures and strict regulations by FDA and Health Canada.
North America holds the largest number of patents. The Asia Pacific has a larger marginal growth than other regions. The market will be supported by Health Canada through research projects and institutions. The Asia Pacific will likely see the most rapid growth during the forecast period. The market’s key driver is expected to be R&D. China and India are among the fastest-growing countries in the Asia Pacific region.
Key Regions and Countries
- The US
- The UK
- Rest of Western Europe
- The Czech Republic
- Rest of Eastern Europe
- South Korea
- Australia & New Zealand
- Rest of APAC
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- United Arab Emirates
- Rest of MEA
Key Players Analysis
The market for in-situ hybridization is very competitive. Because of their vast product portfolios as well as geographic presence, some of the major players accounted for the largest market share. To lower operational expenses and increase profit margins, major players are looking at strategies such as channel enhancement, mergers, acquisitions, operational restructuring, and direct contracts with distributors. Some major key players are:
Маrkеt Кеу Рlауеrѕ
- Thermo Fisher Scientific Inc.
- PerkinElmer, Inc.
- Agilent Technologies, Inc.
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Oxford Gene Technology IP Limited
- Leica Biosystems Nussloch GmbH
- F. Hoffman-La Roche Limited
- ISH for infectious disease diagnosis: In-silico Hybridization is being employed in developing new diagnostic assays for infectious diseases, for instance to detect viruses, bacteria and parasites in tissue samples – potentially leading to faster and more accurate diagnoses of infectious illnesses.
- ISH for cancer diagnosis and prognosis: ISH has become an invaluable way of detecting cancer cells and providing essential data that enables doctors to accurately diagnose cancer, determine its stage, predict treatment efficacy and monitor patients.
- IISH as an aid in drug discovery and development: In vitro siRNA technology is being employed to study how drugs affect gene expression levels, providing invaluable data that could identify new drug targets or develop more efficient therapies.
Report Features Description Market Value (2023) USD 1.5 Billion Forecast Revenue (2033) USD 2.8 Billion CAGR (2024-2033) 6.8% Base Year for Estimation 2023 Historic Period 2018-2022 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered By Technology-(Fluorescent In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH));By Probe Type-( DNA, RNA);By Application-(Cancer, Developmental Biology, Cytogenetics, Infectious Diseases, Other Applications); End-User-(By Research & Diagnostic Laboratories, CROs, Academic Institutes, Other End-Users) Regional Analysis North America-US, Canada, Mexico;Europe-Germany, UK, France, Italy, Russia, Spain, Rest of Europe;APAC-China, Japan, South Korea, India, Rest of Asia-Pacific;South America-Brazil, Argentina, Rest of South America;MEA-GCC, South Africa, Israel, Rest of MEA Competitive Landscape Thermo Fisher Scientific Inc., Abbott, PerkinElmer, Inc., BioView, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited, Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
Frequently Asked Questions (FAQ)What is In situ Hybridization (ISH)?
In situ hybridization is a laboratory technique used to detect and locate specific DNA or RNA sequences within cells or tissues.How big is the In situ Hybridization Market?
The global In situ Hybridization Market size was estimated at USD 1.5 Billion in 2023 and is expected to reach USD 2.8 Billion in 2033.What is the In situ Hybridization Market growth?
The global In situ Hybridization Market is expected to grow at a compound annual growth rate of 6.8%. From 2024 To 2033Who are the key companies/players in the In situ Hybridization Market?
Some of the key players in the In situ Hybridization Markets are Thermo Fisher Scientific Inc., Abbott, PerkinElmer, Inc., BioView, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited, Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited.What Drives the Growth of the In situ Hybridization Market?
The market is driven by factors such as the growing emphasis on precision medicine, expanding applications in cancer research, and the rising demand for diagnostic applications in pathology.What Trends are Shaping the In situ Hybridization Market?
Key trends include the integration of automation and digitalization, as well as the adoption of multiplex in situ hybridization techniques for simultaneous visualization of multiple DNA/RNA sequences.What Challenges does the In situ Hybridization Market Face?
Challenges include the complexity of the technique and the expertise required for accurate interpretation, as well as the cost-intensive nature of advanced techniques, potentially limiting widespread adoption.
| Single User|
USD / per unit
| Multi User|
USD / per unit
| Corporate User|
USD / per unit
|Report Library Access|
|Data Set (Excel)|
|Company Profile Library Access|
|Free Custumization||No||up to 10 hrs work||up to 30 hrs work|
|Accessibility||1 User||2-5 User||Unlimited|
|Analyst Support||up to 20 hrs||up to 40 hrs||up to 50 hrs|
|Benefit||Up to 20% off on next purchase||Up to 25% off on next purchase||Up to 30% off on next purchase|
|Buy Now ($ 3,499)||Buy Now ($ 4,299)||Buy Now ($ 4,999)|